Analysts Set Cryoport, Inc. (NASDAQ:CYRX) Target Price at $11.50

Cryoport, Inc. (NASDAQ:CYRX) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.50.

Several equities research analysts recently commented on CYRX shares. Guggenheim began coverage on Cryoport in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price target on shares of Cryoport in a report on Wednesday, March 5th.

Insider Transactions at Cryoport

In other news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the transaction, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This trade represents a 0.60 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 14,431 shares of company stock worth $80,884 in the last quarter. Company insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bullseye Asset Management LLC lifted its position in Cryoport by 58.7% during the third quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock valued at $1,737,000 after purchasing an additional 79,244 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Cryoport during the 3rd quarter valued at about $3,405,000. Barclays PLC lifted its position in shares of Cryoport by 272.9% during the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock valued at $660,000 after buying an additional 59,582 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of Cryoport by 44.8% during the 4th quarter. SG Americas Securities LLC now owns 146,789 shares of the company’s stock valued at $1,142,000 after buying an additional 45,430 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after purchasing an additional 1,764 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Trading Down 5.3 %

NASDAQ:CYRX opened at $5.84 on Thursday. The company’s 50 day moving average price is $6.92 and its 200-day moving average price is $7.42. Cryoport has a 52 week low of $4.58 and a 52 week high of $20.11. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. The stock has a market cap of $291.47 million, a price-to-earnings ratio of -1.73 and a beta of 1.67.

Cryoport (NASDAQ:CYRX) last issued its earnings results on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The business had revenue of $59.53 million for the quarter, compared to analysts’ expectations of $58.71 million. During the same quarter in the prior year, the business posted ($0.29) earnings per share. On average, equities research analysts forecast that Cryoport will post -0.99 earnings per share for the current fiscal year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.